Circulating Tumor Cells as a Biomarker in Pancreatic Ductal Adenocarcinoma

被引:33
|
作者
Liu, Han [1 ]
Sun, Bo [2 ]
Wang, Shengnan [1 ]
Liu, Congjin [1 ]
Lu, Yun [1 ]
Li, Ding [1 ]
Liu, Xingdang [1 ]
机构
[1] Fudan Univ, Huashan Hosp, Dept Nucl Med, Shanghai, Peoples R China
[2] Fudan Univ, Huashan Hosp, Dept Gen Surg, Shanghai, Peoples R China
关键词
Circulating tumor cells; Pancreatic cancer; Aneuploidy; Biomarker; CANCER PATIENTS; CARCINOMA; SURVIVAL; POLYPLOIDIZATION; IMPROVEMENT; ANEUPLOIDY; DIAGNOSIS; PREDICT; GENOME; BODY;
D O I
10.1159/000477481
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
application for cancer management. In the current study, we evaluated the diagnostic value of CTCs in pancreatic ductal adenocarcinoma (PDAC). Methods: In total, 143 blood samples from 95 consecutively diagnosed PDAC patients and 48 healthy donors were collected. Combined data from immunostaining of CD45, DAPI and fluorescence in situ hybridization (FISH) with chromosome 8 centromere (CEP8) probe were used to identify CTCs. Cells with features of CD45-/DAPI+/CEP8>2 were detected as CTCs. Results: CTCs were classified as triploid, tetraploid and multiploid based on chromosome 8 copy number. CTC subtype composition was significantly different among groups. Both subtype number and total CTC number were significantly increased in PDAC patients, compared to healthy controls. Total CTC number had 75.8% sensitivity and 68.7% specificity at a cutoff value of 2 cells/3.2 mL. This study is the first to report that CTC subtype number is also useful in cancer diagnosis. Sensitivity was 53.7% and specificity was 85.4% at a cutoff point of 2 CTC subtypes. The diagnostic value of both total CTC number and CTC subtype number was a little poorer than CA199. Conclusions: Both CTC subtype and total CTC number may serve as potential biomarkers for PDAC. (C) 2017 The Author(Published by S. Karger AG, Basel
引用
收藏
页码:373 / 382
页数:10
相关论文
共 50 条
  • [31] Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma
    Reiko Takayama
    Hidewaki Nakagawa
    Akira Sawaki
    Nobumasa Mizuno
    Hiroki Kawai
    Masahiro Tajika
    Yasushi Yatabe
    Keitaro Matsuo
    Rie Uehara
    Ken-ichiro Ono
    Yusuke Nakamura
    Kenji Yamao
    Journal of Gastroenterology, 2010, 45 : 52 - 59
  • [32] Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma
    Takayama, Reiko
    Nakagawa, Hidewaki
    Sawaki, Akira
    Mizuno, Nobumasa
    Kawai, Hiroki
    Tajika, Masahiro
    Yatabe, Yasushi
    Matsuo, Keitaro
    Uehara, Rie
    Ono, Ken-ichiro
    Nakamura, Yusuke
    Yamao, Kenji
    JOURNAL OF GASTROENTEROLOGY, 2010, 45 (01) : 52 - 59
  • [33] Circulating tumor DNA methylation as markers for early detection of pancreatic ductal adenocarcinoma (PDAC).
    Liu Xiaoding
    Guo Shiwei
    Ma Chengcheng
    Li Yatong
    Liu Xiaoqian
    Zhang Zhiwen
    Yu Lianyuan
    Dai Menghua
    Shen Shuo
    Wu, Huanwen M.
    Su Zhixi
    He Qiye
    Liu Rui
    Gang Jin
    Liang Zhiyong
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [34] Can circulating tumor and exosomal nucleic acids act as biomarkers for pancreatic ductal adenocarcinoma?
    Liu, Daniel S. K.
    Prado, Mireia Mato
    Giovannetti, Elisa
    Jiao, Long R.
    Krell, Jonathan
    Frampton, Adam E.
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2019, 19 (07) : 553 - 558
  • [35] Diagnostic and prognostic value of KRAS mutations in circulating pancreatic ductal adenocarcinoma tumor DNA
    Yang, Xiaowei
    Xu, Wei
    Tian, Xiuyun
    Wu, Jianhui
    Lv, Ang
    Li, Chengpeng
    Guan, Xiaoya
    Qian, Honggang
    Hao, Chunyi
    TRANSLATIONAL CANCER RESEARCH, 2018, 7 (03) : 622 - 633
  • [36] Clinical utility of circulating tumor DNA (ctDNA) in resectable pancreatic ductal adenocarcinoma (PDAC)
    Wong, Hui-Li
    Bushell, Kevin
    Karasinska, Joanna
    Arthur, Sarah
    Morin, Ryan
    Schaeffer, David F.
    Renouf, Daniel John
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [37] Clinical Significance of Circulating Tumor Microemboli as a Prognostic Marker in Patients with Pancreatic Ductal Adenocarcinoma
    Chang, Ming-Chu
    Chang, Yu-Ting
    Chen, Jia-Yang
    Jeng, Yung-Ming
    Yang, Ching-Yao
    Tien, Yu-Wen
    Yang, Shih-Hung
    Chen, Huai-Lu
    Liang, Ting-Yuan
    Wang, Chien-Fang
    Lee, Eva Y. H. P.
    Chang, Ying-Chih
    Lee, Wen-Hwa
    CLINICAL CHEMISTRY, 2016, 62 (03) : 505 - 513
  • [38] Clinical utility of circulating tumor DNA (ctDNA) in resectable pancreatic ductal adenocarcinoma (PDAC)
    Wong, Hui -Li
    Bushell, Kevin
    Karasinska, Joanna
    Arthur, Sarah
    Morin, Ryan
    Schaeffer, David F.
    Renouf, Daniel John
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [39] Circulating Tumor Cells Expressing Markers of Tumor-Initiating Cells Predict Poor Survival and Cancer Recurrence in Patients with Pancreatic Ductal Adenocarcinoma
    Poruk, Katherine E.
    Blackford, Amanda L.
    Weiss, Matthew J.
    Cameron, John L.
    He, Jin
    Goggins, Michael
    Rasheed, Zeshaan A.
    Wolfgang, Christopher L.
    Wood, Laura D.
    CLINICAL CANCER RESEARCH, 2017, 23 (11) : 2681 - 2690
  • [40] Prognostic Value of Circulating Tumor Cells in Patients With Pancreatic Adenocarcinoma
    Cauley, C. E.
    Pittman, M.
    Zhou, J.
    Valsangkar, N.
    Liss, A.
    Fernandez-del Castillo, C.
    Warshaw, A. L.
    Lillemoe, K. D.
    Thayer, S. P.
    PANCREAS, 2013, 42 (08) : 1342 - 1342